The antidiabetic therapeutic potential of dietary polyphenols

Current Pharmaceutical Biotechnology

Volumn 15, Issue 4, 2014, Pages 391-400

  Habtemariam, Solomon ^a   Varghese, George K ^b  

^a UNIVERSITY OF GREENWICH   (United Kingdom)

^b CMS COLLEGE   (India)

Author keywords

Anti inflammatory; Antioxidant; Diabetes; Enzyme inhibition; Fatty acids metabolism; Glucose metabolism; Polyphenols; Receptor modulation

Indexed keywords

CAFFEIC ACID; CATECHIN; ELLAGIC ACID; EPIGALLOCATECHIN GALLATE; FATTY ACID BINDING PROTEIN 4; GALLIC ACID; GASTROINTESTINAL HORMONE; GLUCOSE TRANSPORTER 4; HYDROXYL RADICAL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR SUBSTRATE; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYPHENOL; PROTEIN KINASE C; QUERCETIN; REACTIVE OXYGEN METABOLITE; SODIUM GLUCOSE COTRANSPORTER; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE; TANNIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ACYL COENZYME A; ADENOSINE PHOSPHATE; AMYLASE; CYANIDIN; CYSTEINE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCOKINASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; FATTY ACID; GLUCOSE;

ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CHEMISTRY; ENZYME INHIBITION; FATTY ACID METABOLISM; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGENOLYSIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIVER FUNCTION; METABOLIC REGULATION; MODULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; RECEPTOR MODULATION; REVIEW; SIGNAL TRANSDUCTION; ARTICLE; CARBOHYDRATE METABOLISM; CELL FUNCTION; CELL SURVIVAL; CHEMICAL STRUCTURE; DIABETES MELLITUS; ENZYME ACTIVITY; GLUCOSE REGULATION SYSTEM; HYPERGLYCEMIA; MACROPHAGE; NONHUMAN; ANIMAL; DIET; DIET THERAPY; DRUG EFFECTS; METABOLISM;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIET; FATTY ACIDS; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; OXIDATIVE STRESS; POLYPHENOLS;

EID: 84907302919     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666140617104643     Document Type: Review

References (156)

1. WHO, 2014-Diabetes: Fact sheet No.312. http://www.who.int/ mediacentre/factsheets/fs312/en/index.html (Accessed March 10, 2014).
2. Whiting, D.R.; Guariguata, L.; Weil, C.; Shaw, J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diab. Res. Clin. Pract., 2011, 94, 311-321.
3. Leto, D.; Saltiel, A.R. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat. Rev. Mol. Cell Biol., 2012, 13(6), 383-396.
4. Braun, M.; Ramracheya, R.; Bengtsson, M.; Zhang, Q.; Karanauskaite, J.; Partridge, C.; Johnson, P.R.; Rorsman, P. Voltage-gated ion channels in human pancreatic β -cells: Electrophysiological characterization and role in insulin secretion. Diabetes, 2008, 57(6), 1618-1628. http://diabetes.diabetesjournals.org/content/57/6/1618.full-aff-1
5. Varela, L.; Horvath, T.L. Leptin and insulin pathways in POMC and AgRP neurons that modulate energy balance and glucose homeostasis. EMBO Rep., 2012, 13, 1079-1086.
6. Mohler, M.L.; He, Y.; Wu, Z.; Hwang, D.J.; Miller, D.D. Recent and emerging anti diabetes targets. Med. Res. Rev., 2009, 29, 125-195.
7. Cade, W.T. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys. Ther., 2008, 88(11), 1322-1335.
8. Bravo, L. Polyphenols: Chemistry, dietary sources, metabolism, and nutritional significance. Nutrit. Rev., 1998, 56(11), 317-333.
9. Sun J.; Prasad, K.N.; Ismail, A.; Yang, B.; You, X.; Li, L. Polyphenols: Chemistry, Dietary Sources and Health Benefits. Nova Science Publishers; 1 edition (November 15, 2012) ISBN-13: 978- 1620818091 pp 23-36.
10. Tsao, R. Chemistry and biochemistry of dietary polyphenols. Nutrients, 2010, 2(12), 1231-1246.
11. Finkel, T. Signal transduction by reactive oxygen species. JCB, 2011, 194(1), 7-15.
12. Wallace, D.C. Mitochondrial defects in cardiomyopathy and neuromuscular disease. Am. Heart J., 2000, 139(Suppl.) S70-S85.
13. Klaunig, J.E; Kamendulis, L.M. The role of oxidative stress in carcinogenesis. Annu. Rev. Pharmacol. Toxicol., 2004, 44, 239-267.
14. Tinahones, F.J.; Murri-Pierri, M.; Garrido-Sánchez, L.; García- Almeida, J.M.; García-Serrano, S.; García-Arnés, J.; García-Fuentes, E. Oxidative stress in severely obese persons is greater in those with insulin resistance. Obesity, 2008, 17, 240-246.
15. Hoehn, K.L.; Salmon, A.B.; Hohnen-Behrens, C.; Turner, N.; Hoy, A.J.; Maghzal, G.J.; Stocker, R.; Van Remmen, H.; Kraegen, E.W.; Cooney, G.J.; Richardson, A.R.; James, D.E. Insulin resistance is a cellular antioxidant defense mechanism. Proc. Natl. Acad. Sci. USA, 2009, 106, 17787-17792.
16. Kesavulu, M.M.; Giri, R.; Rao, B.K.; Apparao, C. Lipid peroxidation and antioxidant enzyme levels in type 2 diabetics with microvascular complications. Diabetes Metab., 2000, 26(5), 387-392.
17. Nishikawa, C T.; Edelstein, D.; Du, X.L.; Yamagishi, S.; Matsumura, T.; Kaneda, Y.; Yorek, M.A.; Beebe, D.; Oates, P.J.; Hammes, H.P.; Giardino, I.; Brownlee, M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 2000, 404(6779), 787-790.
18. Nishikawa, T.; Edelstein, D.; Du, X.L.; Yamagishi, S.; Matsumura, T.; Kaneda, Y.; Yorek, M.A.; Beebe, D.; Oates, P.J.; Hammes, H.P.; Giardino, I.; Brownlee, M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 2000, 404(6779), 787-790
19. Wallace, D.C. Diseases of the mitochondrial DNA. Annu. Rev. Biochem., 1992, 61, 1175-1212.
20. Rice-Evans, C.; Burdon, R. Free radical-lipid interactions and their pathological consequences. Prog. Lipid Res., 1993, 32(1), 71-110.
21. Das, E.N.; Ulusu, N.N.; Karasu, C.; Dogru, B. Adenosine triphosphatase activity of streptozotocin-induced diabetic rat brain microsomes. Effect of vitamin E. Gen. Physiol. Biophys., 2004, 23, 347- 355.
22. Nishimura, C.; Hotta, Y.; Gui, T.; Seko, A.; Fujimaki, T.; Ishikawa, T.; Hayakawa, M.; Kanai, A.; Saito, T. The level of erythrocyte aldose reductase is associated with the severity of diabetic retinopathy. Diabetes Res. Clin. Pract., 1997, 37, 173-177.
23. Houstis, N.; Rosen, E.D.; Lander, E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature, 2006, 440(7086), 944-948.
24. Nakamura, S.; Makita, Z.; Ishikawa, S.; Yasumura, K.; Fujii, W.; Yanagisawa, K.; Kawata, T.; Koike, T. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes, 1997, 46, 895-899.
25. Du, Y.; Miller, C.M.; Kern, T.S. Hyperglycemia increases mitochondrial superoxide in retina and retinal cells. Free Radic. Biol. Med., 2003, 35, 1491-1499.
26. Brownlee, M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes, 2005, 54(6), 1615-1625.
27. Schleicher, E.D.; Weigert, C. Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney Int., 2000, 77(Suppl.), S13-S18.
28. Houstis, N.; Rosen, E.D.; Lander, E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature, 2006, 440(7086), 944-948.
29. Jain, S.K.; Velusamy, T.; Croad, J.L.; Rains, J.L.; Bull, R. Cysteine supplementation lowers blood glucose, glycated hemoglobin, CRP, MCP-1, and oxidative stress and inhibits NF-[kappa]B activation in the livers of Zucker diabetic rats. Free Radic. Biol. Med., 2009, 46(12), 1633-1638.
30. Muellenbach, E.M.; Diehl, C.J.; Teachey, M.K.; Lindborg, K.A.; Hasselwander, O.; Matuschek, M.; Henriksen, E.J. Metabolic interactions of AGE inhibitor pyridoxamine and antioxidant [alpha]- lipoic acid following 22 weeks of treatment in obese Zucker rats. Life Sci., 2009, 84(15-16), 563-568.
31. 2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J. Clin. Invest., 2009, 119(3), 573-581.
32. Weisberg, S.P.; McCann, D.; Desai, M.; Rosenbaum, M.; Leibel, R.L.; Ferrante, A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Investig., 2013, 112(12), 1796-808.
33. Johnson, A.M.; Olefsky, J.M. The origins and drivers of insulin resistance. Cell, 2013, 152(4), 673-684.
34. Heilbronn, L.K.; Campbell, LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr. Pharm. Des., 2008, 14(12), 1225-1230.
35. Hotamisligil, G.S. Mechanisms of TNF-alpha-induced insulin resistance. Exp. Clin. Endocrinol. Diabet., 1999, 107(2), 119-125.
36. Shoelson, S.E.; Lee, J.; Goldfine, A.B. Inflammation and insulin resistance. J. Clin. Invest., 2006, 116(7), 1793-1801.
37. Senn, J.J.; Klover, P.J.; Nowak, I.A.; Mooney, R.A. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes, 2002, 51(12), 3391-3399.
38. Lee Y.H.; Giraud, J.; Davis R.J.; White M.F. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J. Biol. Chem., 2003, 278(5), 2896-2902.
39. Gómez-Zorita, S.; Fernández-Quintela, A.; Lasa, A.; Hijona, E.; Bujanda, L.; Portillo, M.P. Effects of resveratrol on obesity-related inflammation markers in adipose tissue of genetically obese rats. Nutrition, 2013, 29(11-12), 1374-1380.
40. Kim, P.H.; Son, K.H.; Chang, H.W.; Kang, S.S. Anti-inflammatory plant flavonoids and cellular action mechanisms. J. Pharmacol. Sci., 2004, 96(3), 229-245.
41. Sears, B.; Ricordi, C. Role of fatty acids and polyphenols in inflammatory gene transcription and their impact on obesity, metabolic syndrome and diabetes. Eur. Rev. Med. Pharmacol. Sci., 2012, 16(9), 1137-1154.
42. Siriwardhana, N.; Kalupahana, N.S.; Cekanova, M.; LeMieux, M.; Greer, B.; Moustaid-Moussa, N. Modulation of adipose tissue inflammation by bioactive food compounds. J. Nutr. Biochem., 2013, 24(4), 613-623.
43. Miehle, K.; Stepan, H.; Fasshauer, M. Leptin, adiponectin and other adipokines in gestational diabetes mellitus and pre-eclampsia. Clin. Endocrinol. (Oxf)., 2012, 76(1), 2-11.
44. Chacón, M.R.; Fernández-Real, J.M.; Richart, C.; Megía, A.; Gómez, J.M.; Miranda, M.; Caubet, E.; Pastor, R.; Masdevall, C.; Vilarrasa, N.; Ricard, W.; Vendrell, J. Monocyte chemoattractant protein-1 in obesity and type 2 diabetes. Insulin sensitivity study. Obesity, 2007, 15(3), 664-72.
45. Okapcova, J.; Gabor, D. The levels of soluble adhesion molecules in diabetic and nondiabetic patients with combined hyperlipoproteinemia and the effect of ciprofibrate therapy. Angiology, 2004, 55(6), 629-639.
46. Xu, R.; Yang, R.; Hu, H.; Xi, Q.; Wan, H.; Wu, Y. Diabetes alters the expression of partial vasoactivators in cerebral vascular disease susceptible regions of the diabetic rat. Diabetol. Metab. Synd., 2013, 5, 63.
47. Berg, A.H.; Scherer, P.E. Adipose tissue, inflammation, and cardiovascular disease. Circul. Res., 2005, 96(9), 939-949.
48. Kim, J.; Montagnani, M.; Koh, K.K.; Quon, M.J. Reciprocal relationships between Insulin resistance and endothelial dysfunction. Molecular and pathophysiological mechanisms. Circulation, 2006, 113(15), 1888-1904.
49. Dandona, P.; Chaudhuri, A.; Ghanim, H.; Mohanty, P. Insulin as an anti-inflammatory and antiatherogenic modulator. J. Am. Coll. Cardiol., 2009, 53(5 Supp), S14-S20.
50. Rahman, I.; Gilmour, P.S.; Jimenez, L.A.; MacNee, W. Oxidative stress and TNF-alpha induce histone acetylation and NFkappaB/ AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation. Mol. Cell. Biochem., 2002, 234-235(1-2), 239-248.
51. Larsen, C.M.; Faulenbach, M.; Vaag, A.; Vølund, A.; Ehses, J.A.; Seifert, B.; Mandrup-Poulsen, T.; Donath, M.Y. Interleukin-1- receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med., 2007, 356(15), 1517-1526.
52. Hundal, R.S.; Petersen, K.F.; Mayerson, A.B.; Randhawa, P.S.; Inzucchi, S.; Shoelson, S.E.; Shulman, G.I. Mechanism by which high dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest., 2002,109(10), 1321-1326.
53. Gao, Z.; Zuberi, A.; Quon, M.J.; Dong, Z.; Ye, J. Aspirin inhibits serine phosphorylation of insulin receptor substrate-1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. J. Biol. Chem., 2003, 278(27), 24944-24950.
54. Goldfine, A.B.; Fonseca, V.; Jablonski, K.A.; Pyle, L.; Staten, M.A.; Shoelson, S.E. Targeting inflammation using salsalate in type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabet. Care, 2013, 36(12), 4132-4139.
55. Palaska, I.; Papathanasiou, E.; Theoharides, T.C. Use of polyphenols in periodontal inflammation. Eur. J. Pharmacol., 2013, 720(1- 3), 77-83.
56. Hamer, M. The beneficial effects of tea on immune function and inflammation: a review of evidence from in vitro, animal, and human research. Nutr. Res., 2007, 27(7), 373-379.
57. Kim, H.P.; Son, K.H.; Chang H.W.; Kang, S.S. Anti-inflammatory plant flavonoids and cellular action mechanisms. J. Pharmacol. Sci., 2004, 96(3), 229-245.
58. Habtemariamn, S. Natural inhibitors tumour necrosis factor-a production, secretion and function. Planta Med., 2000, 66(4), 303-313.
59. Habtemartiam, S. Targeting the production of monocytes/ macrophages-derived cytokines by anti-inflammatory herbal drugs. Phytopharmacology, 2013, 4(1), 131-148.
60. Nicolle, E.; Souard, F.; Faure, P.; Boumendjel, A. Flavonoids as promising lead compounds in type 2 diabetes mellitus: molecules of interest and structure-activity relationship. Curr. Med. Chem., 2011, 18(17), 2661-2672.
61. Babu, P.V.; Liu, D.; Gilbert, E.R. Recent advances in understanding the anti-diabetic actions of dietary flavonoids. J. Nutr. Biochem., 2013, 24(11), 1777-1189.
62. Anhê, F.F.; Desjardins, Y.; Pilon, G.; Dudonné, S.; Genovese, M.I.; Lajolo, F.M.; Marette, A. Polyphenols and type 2 diabetes: A prospective review. Pharma. Nutrit., 2013, 1(4), 105-114.
63. Lee, S-H.; Jeon, Y-H. Anti-diabetic effects of brown algae derived phlorotannins, marine polyphenols through diverse mechanisms. Fitoterapia, 2013, 86, 129-136.
64. Zhang, D.W.; Fu, M.; Gao, S.H.; Liu, J.L. Curcumin and diabetes: A systematic review. Evid. Based Complement. Alternat. Med., 2013, 2013, 636053.
65. Vazquez-Prieto, M.A., Bettaieb, A.; Haj, F.G.; Fraga, C.G.; Oteiza, P.I. (-)-Epicatechin prevents TNFα-induced activation of signaling cascades involved in inflammation and insulin sensitivity in 3T3- L1 adipocytes. Arch. Biochem. Biophys., 2012, 527(2),113-118.
66. Kalhan, S.C. Fatty Acids, Insulin Resistance, and ProteinMetabolism. J. Clin. Endocrinol. Metab., 2009, 94(8), 2725-2727.
67. Kruszynska, Y.T.; Worrall, D.S.; Ofrecio, J.; Frias, J.P.; Macaraeg, G.; Olefsky, J.M. Fatty acid-induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation. J. Clin. Endocrinol. Metab., 2002, 87(1), 226-234.
68. Teruel, T.; Hernandez, R.; Lorenzo, M. Ceramide mediates insulin resistance by tumor necrosis factor-α in brown adipocytes by maintaining Akt in an inactive dephosphorylated state. Diabetes, 2001, 50(11), 2563-2571.
69. Cefalu, W.T. Inflammation, Insulin Resistance, and Type 2 Diabetes: Back to the Future? Diabetes, 2009, 58(2), 307-308.
70. Hull, R.L.; Andrikopoulos, S.; Verchere, C.B.; Vidal, J.; Wang, F.; Cnop, M.; Prigeon, R.L.; Kahn, S.E. Increased dietary fat promotes islet amyloid Formation and β-Cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes, 2003, 52(2), 372-379.
71. Furukawa, S.; Fujita, T.; Shimabukuro, M.; Iwaki, M.; Yamada, Y.; Nakajima, Y.; Nakayama, O.; Makishima, M.; Matsuda, M.; Shimomura, I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest., 2004, 114(12), 1752-1761.
72. Inoguchi, T.; Li, P.; Umeda, F.; Yu, H.Y.; Kakimoto, M.; Imamura, M.; Aoki, T.; Etoh, T.; Hashimoto, T.; Naruse, M.; Sano, H.; Utsumi, H.; Nawata, H. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes, 2000, 49(11), 1939-1945.
73. Viollet, B.; Andreelli F. AMP-activated protein kinase and metabolic control. Handb Exp. Pharmacol., 2011, 203, 303-330.
74. Sarre, A.; Gabrielli, J.; Vial, G.; Leverve, X.M.; Assimacopoulos-Jeannet, F. Reactive oxygen species are produced at low glucose and contribute to the activation of AMPK in insulin-secreting cells. Free Radic. Biol. Med., 2012, 52(1), 142-150.
75. Guan, Y-F.; Breyer, M.D. Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Kidney Int., 2001, 60(1), 14-30.
76. Chawla, A. Control of macrophage activation and function by PPARs. Circulation Res., 2010, 106, 1559-1569.
77. Astapova, O.; Leff, T. Adiponectin and PPARγ: cooperative and interdependent actions of two key regulators of metabolism. Vitam. Horm., 2012, 90, 143-162.
78. Hevener, A.L.; Olefsky, J.M.; Reichart, D; Nguyen, M.T.; Bandyopadyhay, G.; Leung, H-Y.; Watt, M.J.; Benner, C.; Febbraio, M.A.; Nguyen, A.K.; Folian, B.; Subramaniam, S.; Gonzalez, F.J.; Glass, C.K.; Ricote, M. Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Investig., 2007, 117(6), 1658-1669.
79. Muoio, D.M.; Way, J.M.; Tanner, C.J.; Winegar, D.A.; Kliewer, S.A.; Houmard, J.A.; Kraus, W.E.; Dohm, G.L. Peroxisome proliferator- activated receptor-α regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes, 2002, 51(4), 901-909.
80. Watkins, P.A.; Ellis, J.M. Peroxisomal acyl-CoA synthetases. Biochim. Biophys. Acta (BBA)-Molecul. Basis Dis., 2012, 1822(9), 1411-1420.
81. Cai, Y.; Fan, C.; Yan, J.; Tian, N.; Ma, X. Effects of rutin on the expression of PPARγ in skeletal muscles of db/db mice. Planta Med., 2012, 78(9), 861-865.
82. Scazzocchio, B.; Varì, R.; Filesi, C.; D'Archivio, M.; Santangelo, C.; Giovannini, C.; Iacovelli, A.; Silecchia, G.; Li-Volti, G.; Galvano, F.; Masella, R. Cyanidin-3-O-β-glucoside and protocatechuic acid exert insulin-like effects by upregulating PPARγ activity in human omental adipocytes. Diabetes, 2011, 60(9), 2234-2244.
83. Wang, S.; Moustaid-Moussa, N.; Chen, L.; Mo, H.; Shastri, A.; Su, R.; Bapat, P.; Kwun, I.; Shen, C-L. Novel insights of dietary polyphenols and obesity. J. Nutr. Biochem., 2004, 25(1), 1-18.
84. Rains, T.M.; Agarwal, S.; Maki, K.C. Antiobesity effects of green tea catechins: a mechanistic review. J. Nutr. Biochem., 2011, 22(1), 1-7.
85. Thielecke, F.; Boschmann, M. The potential role of green tea catechins in the prevention of the metabolicsyndrome-A review. Phytochemistry, 2009, 70(1), 11-24.
86. Lim, H.A.; Lee, E.K.; Kim, J.M.; Park, M.H.; Kim, D.H.; Choi, Y.J.; Ha, Y.M.; Yoon, J.H.; Choi, J.S.; Yu, B.P.; Chung, H.Y. PPARγ activation by baicalin suppresses NF-κB-mediated inflammation in aged rat kidney. Biogerontology, 2012, 13(2), 133-145.
87. Ong, K.W.; Hsu, A.; Tan, B.K. Anti-diabetic and anti-lipidemic effects of chlorogenic acid are mediated by ampk activation. Biochem. Pharmacol., 2013, 85(9), 1341-1351.
88. Pu, P.; Wang, X.A.; Salim, M.; Zhu, L.H.; Wang, L.; Chen, K.J.; Xiao, J.F.; Deng, W.; Shi, H.W.; Jiang, H.; Li, H.L. Baicalein, a natural product, selectively activating AMPKα(2) and ameliorates metabolic disorder in diet-induced mice. Mol. Cell Endocrinol., 2012, 362(1-2), 128-138.
89. Saito, T.; Abe, D.; Sekiya, K. Flavanone exhibits PPARgamma ligand activity and enhances differentiation of 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun., 2009, 380(2), 281-285.
90. Meydani, M.; Hasan, T.S. Dietary polyphenols and obesity. Nutrients, 2010, 2(7), 737-751.
91. Fukuchi, Y.; Hiramitsu, M.; Okada, M.; Hayashi, S.; Nabeno, Y.; Osawa, T.; Nai, M. Lemon polyphenols suppress diet-induced obesity by up-regulation of mRNA Levels of the enzymes involved in β -oxidation in mouse white adipose tissue. J. Clin. Biochem. Nutr., 2008, 43(3), 201-209.
92. Jia, Y, Kim, J.Y.; Jun, H.J.; Kim, S.J.; Lee, J.H.; Hoang, M.H.; Kim, H.S.; Chang, H.I.; Hwang, K.Y.; Um, S.J.; Lee, S.J. Cyanidin is an agonistic ligand for peroxisome proliferator-activated receptor- alpha reducing hepatic lipid. Biochem. Biophys. Acta., 2013, 1831(4), 698-708.
93. de Sales, P.M.; de Souza, P.M.; Simeoni, L.A.; Magalhães, P.D.O.; Silveira, D. α-Amylase inhibitors: A review of raw material and isolated compounds from plant source. J. Pharm. Sci., 2012, 15(1), 141-183.
94. Xiao, J.; Kai, G.; Yamamoto, K.; Chen, X. Advance in dietary polyphenols as α-glucosidases inhibitors: a review on structureactivity relationship aspect. Crit. Rev.Food. Sci. Nutr., 2013, 53(8), 818-836.
95. Tundis, R; Loizzo, M.R.; Menichini F. Natural products as alphaamylase and alpha-glucosidase inhibitors and their hypoglycaemic potential in the treatment of diabetes: An update. Mini Rev. Med. Chem., 2010, 10(4), 315-331.
96. Habtemariam, S. α-Glucosidase inhibitory activity of kaempferol- 3-O-rutinoside. Nat. Prod. Commun., 2011, 6(2), 201-203.
97. Roselli, M.; Lentini, G.; Habtemariam, S. Phytochemical, antioxidant and anti-alpha-glucosidase activity evaluations of Bergenia cordifolia. Phytother. Res., 2012, 26(6), 908-914.
98. Wright, E.M.; Loo, D.D.F.; Hirayama, B.A. Biology of human sodium glucose transporters. Physiol. Rev., 2011, 91(2), 733-794.
99. Tahrani, A.A.; Barnett, A.H.; Bailey, C.J. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol., 2013, 1(2), 140-151.
100. Qian, M.; Spinelli, S.; Driguez, H.; Payan, F. Structure of a pancreatic a-amylase bound to a substrate analogue at 2.03 a resolution. Protein Sci., 1997, 6(11), 2285-2296.
101. Ader, A.; Blöck, M.; Pietzsch, S.; Wolffram, S. Interaction of quercetin glucosides with the intestinal sodium/glucose co-transporter (SGLT-1). Cancer Lett., 2001, 162(2), 175-180.
102. Chen, C.H.; Hsu, H.J.; Huang, Y.J.; Lin, C.J. Interaction of flavonoids and intestinal facilitated glucose transporters. Planta Med., 2007, 73(4), 348-354.
103. Guschlbauer, M., Klinger, S.; Burmester, M.; Horn, J.; Kulling, S.E.; Breves, G. trans-Resveratrol and ε-viniferin decreaseglucose absorption in porcine jejunum and ileum in vitro. Comp. Biochem. Physiol. A Mol. Integr. Physiol., 2013, 165(3), 313-318.
104. Johnston, K.; Sharp, P.; Clifford, M.; Morgan, L. Dietary polyphenols decrease glucose uptake by human intestinal Caco-2 cells. FEBS Lett., 2005, 579(7), 1653-1657.
105. Kwon, O.; Eck, P.; Chen, S.; Corpe, C.P.; Lee, J-H.; Kruhlak, M.; Levine, M. Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. FASEB J., 2007, 21(2), 366-377. http://www.fasebj.org/content/21/2/366.long-corresp-1
106. Shimizu, M.; Kobayashi, Y.; Suzuki, M.; Satsu, H.; Miyamoto, Y. Regulation of intestinal glucose transport by tea catechins. Biofactors, 2000, 13(1-4), 61-65.
107. Bryant, N.J.; Govers, R.; James, D.E. Regulated transport of the glucose transporter GLUT4. Nat. Rev. Mol. Cell Biol., 2002, 3(4), 267-277.
108. Lee, J.O.; Lee, S.K.; Kim, J.H.; Kim, N.; You, G.Y.; Moon, J.W.; Kim, S.J.; Park, S.H.; Kim, H.S. Metformin regulates glucose transporter 4 (GLUT4) translocation through AMP-activatedprotein kinase (AMPK)-mediated Cbl/CAP signaling in 3T3-L1 preadipocyte cells. J. Biol. Chem., 2012, 287(53), 44121-44129.
109. Huang, S.; Czech, M.P. Cell Metabolism-The GLUT4 glucose transporter. Cell Metab., 2007, 5(4), 237-252.
110. Watson R.T.; Pessin, J.E. Bridging the GAP between insulinsignaling and GLUT4 translocation TRENDS in Biochemical Sciences. 2006, 31(4), 215-222.
111. Li, L.; Chen, H.; McGee, S.L. Mechanism of AMPK regulating GLUT4 gene expression in skeletal muscle cells. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi., 2008, 25(1), 161-167.
112. Kim, M.S.; Hur, H.J.; Kwon, D.Y.; Hwang, J.T. Tangeretin stimulates glucose uptake via regulation of AMPK signaling pathways in C2C12 myotubes and improves glucose tolerance in high-fat dietinduced obese mice. Mol. Cell. Endocrinol., 2012, 358(1), 127-34.
113. Li, Y.; Zhao, S.; Zhang, W.; Zhao, P.; He, B.; Wu, N.; Han, P. Epigallocatechin-3-O-gallate (EGCG) attenuates FFAs-induced peripheral insulin resistance through AMPK pathway and insulin signaling pathway in vivo. Diabetes Res. Clin. Pract., 2011, 93(2), 205-214.
114. Daisy, P.; Balasubramanian, K.; Rajalakshmi, M.; Eliza, J.; Selvaraj, J. Insulin mimetic impact of Catechin isolated from Cassia fistula on the glucose oxidation and molecular mechanisms of glucose uptake on Streptozotocin-induced diabetic Wistar rats. Phytomedicine, 2010, 17(1), 28-36.
115. Cordero-Herrera, I.; Martín, M.A.; Goya, L.; Ramos, S. Cocoa flavonoidsattenuate high glucose-induced insulin signalling blockade and modulate glucoseuptake and production in human HepG2 cells. Food Chem. Toxicol., 2014, 64C, 10-19.
116. Do, G.M.; Jung, U.J.; Park, H.J.; Kwon, E.Y.; Jeon, S.M.; McGregor, R.A., Choi, M.S. Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice. Mol. Nutr. Food Res., 2012, 56(8), 1282-1291.
117. Alonso-Castro, A.J.; Miranda-Torres, A.C.; González-Chávez, M.M.; Salazar-Olivo L.A. Cecropia obtusifolia Bertol and its active compound, chlorogenic acid, stimulate 2-NBDglucose uptake in both insulin-sensitive and insulin-resistant 3T3 adipocytes. J. Ethnopharmacol., 2008, 120(3), 458-464.
118. Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem. J., 2008, 414(1), 1-18.
119. María L.M.; Juan, J.G.; Flavio, F. Liver glucokinase: An overview on the regulatory mechanisms of its activity. IUBMB Life, 2011, 63(1), 1-6
120. Ynedjian, P. B. Mammalian glucokinase and its gene. Biochem. J., 1993, 293(1), 1-13.
121. Agius, L. Targeting hepatic glucokinase in type 2 diabetes. Weighing the benefits and risks. Diabetes, 2009, 58(1), 18-0.
122. Wolffram, S.; Blöck, M.; Ader, P. Quercetin-3-glucoside is transported by the glucose carrier SGLT1 across the brush border membrane of rat small intestine. J. Nutr., 2002, 132(4), 630-635.
123. Jung, U.J.; Lee, M.K.; Jeong, K.S.; Choi, M.S. The hypoglycemic effects of hesperidinand naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-db/db mice. J. Nutr., 2004, 134(10), 2499-2503.
124. Bhattacharya, S.; Oksbjerg, N.; Young, J.F.; Jeppesen, P.B. Caffeic acid, naringenin and quercetin enhance glucose-stimulated insulin secretion and glucose sensitivity in INS-1E cells. Diabetes Obes. Metab., 2013, In Press.
125. Harini, R. Pugalendi, K.V.J. Antihyperglycemic effect of protocatechuic acid on streptozotocin-diabetic rats. Basic Clin. Physiol. Pharmacol., 2010, 21(1), 79-91.
126. Kim, J.J.; Tan, Y.; Xiao, L.; Sun, Y.L.; Qu, X. Green tea polyphenol epigallocatechin-3-gallate enhance glycogen synthesis and inhibit lipogenesis in hepatocytes. Biomed. Res. Int., 2013, In Press
127. Collins, Q.F.; Liu, H.Y.; Pi, J.; Liu, Z.; Quon, M.J.; Cao, W. Epigallocatechin- 3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5'-AMP-activated protein kinase. J. Biol. Chem., 2007, 282(41), 30143-30149.
128. Waltner-Law, M.E.; Wang, X.L.; Law, B.K.; Hall, R.K.; Nawano, M.; Granner, D.K. Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production. J. Biol. Chem., 2002, 277(38), 34933-34940.
129. Mulder, H.; Ling, C. Mitochondrial dysfunction in pancreatic β- cells in Type 2 Diabetes. Mol. Cell. Endocrinol., 2009, 297(1-2), 34-40.
130. Butler, A.E.; Janson, J.; Bonner-Weir, S.; Ritzel, R.; R.A.; Rizza, R.A.; Butler, P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes, 2003, 52(1), 102-110.
131. Cnop, M.; Welsh, N.; Jonas, J-C.; Jo A.; Lenzen, S.; Eizirik, D.L. Mechanisms of Pancreatic-cell death in type 1 and type 2 diabetes. Many differences, few Similarities. Diabetes, 2005, 2(Supp. 54), S97-S10.
132. Yang, H.; Jin, X.; Kei-Lam, C.W.; Yan, S.K. Oxidative stress and diabetes mellitus. Clin. Chem. Lab. Med., 2011, 49(11), 1773-1782.
133. Coskun, O.; Kanter, M.; Korkmaz, A.; Oter, S. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. Pharmacol., Res., 2005, 51(2), 117-123.
134. Esmaeili, M.A.; Sadeghi, H. Pancreatic B-Cell Protective Effect of Rutin and Apigenin Isolated from Teucrium Polium. Pharmacology online, 2009, 2, 341-353.
135. Lin, C.Y.; Ni, C.C.; Yin, M.C.; Lii, C.K. Flavonoids protect pancreatic beta-cells from cytokines mediated apoptosis through the activation of PI3-kinase pathway. Cytokine, 2012, 59(1), 65-71.
136. Kim, E.K.; Kwon, K.B.; Song, M.Y.; Han, M.J.; Lee, J.H.; Lee, Y.R.; Lee, J.H.; Ryu, D.G.; Park, B.H.; Park, J.W. Flavonoids protect against cytokine-induced pancreatic beta-cell damage through suppression of nuclear factor kappaB activation. Pancreas, 2007, 35(4), e1-9.
137. Cai, E.P.; Lin, J.K. Epigallocatechin gallate (EGCG) and rutin suppress the glucotoxicity through activating IRS2 and AMPK signaling in rat pancreatic betacells. J. Agric. Food Chem., 2009, 57(20), 9817-9827.
138. Yun, S-Y.; Kim, S-P.; Song, D-K. Effects of (-)-epigallocatechin- 3-gallate on pancreatic beta-cell damage in streptozotocin-induced diabetic rats. Eur. J. Pharmacol., 2006, 541(1-2), 115-121.
139. Bryan, J.; Crane, A.; Vila-Carriles, W.H.; Babenko, A.P.; Aguilar- Bryan, L. Insulin secretagogues, sulfonylurea receptors and K(ATP) channels. Curr. Pharm. Des., 2005, 11(21), 2699-2716.
140. Hii, C.S.; Howell, S.L. Effects of flavonoids on insulin secretion and 45Ca2+ handling in rat islets of Langerhans. J. Endocrinol., 1985, 107(1), 1-8.
141. Pinent, M.; Castell, A.; Baiges, I.; Montagut, G.; Arola, L.; Ard́evol, A. Bioactivity of flavonoids on insulin-secreting cells. Comprehens. Rev. Food Sci. Food Safety, 2008, 7(4), 299-308.
142. Yang, G.; Lucas, R.; Caldwell, R.; Yao, L.; Romero, M.J.; Caldwell, R.W. Novel mechanisms of endothelial dysfunction in diabetes. J. Cardiovasc. Dis. Res., 2010, 1(2), 59-63.
143. Adisakwattana, S.; Moonsan, P.; Yibchok-Anun, S. Insulinreleasing properties of a series of cinnamic acid derivatives in vitro and in vivo. J. Agric. Food Chem. 2008, 56(17), 7838-7844.
144. Ganugapati, J.; Mukkavalli, S.; Sahithi, A. Docking studies of green tea flavonoids as insulin mimetics. Inter. J. Comp. App., 2011, 30(4), 48-52.
145. Li, C.; Li, M.; Chen, P.; Narayan, S.; Matschinsky, FM.; Bennett, MJ.; Stanley, CA,; Smith, TJ. Green tea polyphenols control dysregulated glutamate dehydrogenase in transgenic mice by hijacking the ADP activation site. J. Biol. Chem., 2011, 286(39), 34164-34174.
146. Jayaprakasam, B.; Vareed, S.K.; Olson, L.K.; Nair, M.G. Insulin secretion by bioactive anthocyanins and anthocyanidins present in fruits. J. Agric. Food Chem., 2005, 53(1), 28-31.
147. Fu, Z.; Liu, D. Long-term exposure to genistein improves insulin secretory function of pancreatic beta-cells. Eur. J. Pharmacol., 2009, 616(1-3), 321-327.
148. Baggio, L.L.; Drucker, D.J. Biology of incretins: GLP-1 and GIP. Terology, 2007, 132(6), 2131-57.
149. American Diabetes Association. DPP-4 Inhibitors. Impact on glycemic control and cardiovascular risk factors. http://care.diabetesjournals.org/content/34/Supplement_2/S276.extract
150. Fan, J.; Johnson, M.H.; Lila, M.A.; Yousef, G.; de Mejia E.G. Berry and citrus phenolic compounds inhibit dipeptidyl peptidase IV: Implications in diabetes management. Evidence-Based Comp. Alter. Med., 2013, http://dx.doi.org/10.1155/2013/479505.
151. Tawani, A.; Tiwari, V.; Manivannan, E.; Kumar, A. DPP-IV inhibitory potential of naringin: an in silico, in vitro and in vivo study. Diabetes Res. Clin. Pract., 2012, 97(1), 105-111.
152. Meier, J.J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature Rev. Endocrinol., 2012, 8(12), 728-742.
153. Reaven, G.M. Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: similarities and differences. J. Clin. Hyper. (Greenwich, Conn.), 2011, 13(4), 238-243.
154. Noordzij, M.J.; Mulder, D.J.; Oomen, P.H.; Brouwer, T.; Jager, J.; Cabezas, M.C.; Lefrandt, J.D.; Smit, A.J. Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study. Diabetic Med., 2012, 29(12), 1556-1561.
155. Li, F.Y.L; Lam, K.S.; Tse, H.F.; Chen, C.; Wang, Y.; Vanhoutte, P.M.; Xu, A. Endothelium-selective activation of AMP-activated protein kinase prevents diabetes mellitus-induced impairment in vascular function and reendothelialization via induction of heme oxygenase-1 in mice/clinical perspective. Circulation, 2012, 126(10), 1267-1277.
156. Santino, A.; Taurino, M.; Ingrosso, I.; Giovinazzo, G. In: From Plant Genomics to Plant Biotechnology; Chapter 12 - Natural resveratrol bioproduction. Poltronieri, P.; Burbulis, N.; Fogher, C., Ed; Woodhead Publishing, Cambridge, 2013, 223-234.